Aclarion, Inc.

ACON Nasdaq CIK: 0001635077

Company Information

Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 8181 ARISTA PLACE, BROOMFIELD, CO, 80021
Mailing Address 8181 ARISTA PLACE, BROOMFIELD, CO, 80021
Phone 833 275 2266
Fiscal Year End 1231
EIN 473324725

Financial Overview

FY2025

$1.15M
Total Liabilities
$12.84M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G Passive beneficial ownership (>5%) March 25, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
10-K Annual financial report March 18, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC
424B5 Prospectus supplement January 9, 2026 View on SEC
4 Insider stock transaction report December 1, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC
8-K Current report of material events October 14, 2025 View on SEC
424B5 Prospectus supplement October 14, 2025 View on SEC

Annual Reports

10-K March 18, 2026
  • Aclarion achieved a significant 50% revenue increase to $1.2 million in 2025, indicating early market traction for its diagnostic platform.
  • The company successfully completed enrollment for a pivotal clinical trial for its flagship diagnostic product, with preliminary data expected in late 2026.
View Analysis

Material Events

8-K Strategy Change March 19, 2026
High Impact
  • Protects existing shareholders from hostile takeovers, ensuring a fair price for the company.
  • Strengthens the Board's position in negotiations, allowing them to secure the best deal for all shareholders.
View Analysis

Related Companies

Companies in the same industry (SIC: 8071)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.